Abstract
Introduction: The programmed death-1 (PD-1) immune checkpoint pathway is an emerging target in the treatment of hematologic malignancies. Pidilizumab is an mAb that binds to PD-1 and is a safe and well-tolerated therapy. Recent data have shown clinical activity utilizing this strategy in diffuse large B-cell lymphoma (DLBCL).Areas covered: The role of PD-1 expression in hematologic malignancies is explored. Recent clinical trials including the results of a Phase I trial in hematologic malignancies and a Phase II trial of pidilizumab following autologous hematopoietic stem-cell transplant (AHSCT) are reviewed.Expert opinion: We review data that suggest that PD-1 is a promising target in the treatment and management of DLBCL. Changes in immune subsets following administration of pidilizumab are felt to represent on-target responses. The improvement in progression-free survival (PFS) following AHSCT supports a response to therapy. Importantly, the improvement in PFS for patients with positive FDG-PET/CT following AHSCT indicating residual disease further supports direct activity of pidilizumab in DLBCL.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1361-1368 |
| Number of pages | 8 |
| Journal | Expert Opinion on Biological Therapy |
| Volume | 14 |
| Issue number | 9 |
| DOIs | |
| State | Published - Sep 2014 |
| Externally published | Yes |
Keywords
- Diffuse large B-cell lymphoma
- Monoclonal antibody
- Non-Hodgkin lymphoma
- Pidilizumab
- Programmed death-1
ASJC Scopus subject areas
- Pharmacology
- Drug Discovery
- Clinical Biochemistry